TORONTO, March 16, 2015 /CNW/ - Concordia Healthcare Corp. ("Concordia" or "the Company") (TSX: CXR) (OTCQX: CHEHF), today announced it will release its fourth
quarter and year-end 2014 financial results after market close on
Thursday, March 19, 2015.
The Company will subsequently hold a conference call on Friday, March
20, 2015, at 8:30 a.m. ET hosted by Mr. Mark Thompson, President and
Chief Executive Officer, Mr. Leith Tessy, Chief Financial Officer, and
Mr. Wayne Kreppner, Chief Operating Officer. A question-and-answer
session will follow the corporate update.
CONFERENCE CALL DETAILS
Friday, March 20, 2015
8:30 a.m. ET
(647) 427-7450 or (888) 231-8191
(416) 849-0833 or (855) 859-2056
This call is being webcast and can be accessed from the Concordia
website at www.concordiarx.com or by going to http://www.newswire.ca/en/webcast/detail/1499535/1670573
An archived replay of the webcast will be available for one year.
Concordia is a diverse healthcare company focused on legacy
pharmaceutical products and orphan drugs. Concordia's legacy
pharmaceutical division, Concordia Pharmaceuticals Inc., consists of
the following products: ADHD-treatment Kapvay® (clonidine extended
release tablets), head lice treatment Ulesfia® (benzyl alcohol) Lotion,
asthma-related medication Orapred ODT® (prednisolone sodium phosphate
orally disintegrating tablets), irritable bowel syndrome treatment
Donnatal® (belladonna alkaloids, phenobarbital) and Zonegran®
(zonisamide) for treatment of partial seizures in adults with epilepsy.
Concordia's specialty healthcare distribution (SHD) division, Complete
Medical Homecare, distributes medical supplies targeting diabetes and
related conditions. Concordia's orphan drugs division, Concordia
Laboratories Inc., manufactures PHOTOFRIN®. PHOTOFRIN® is marketed by
Pinnacle Biologics, Inc. in the United States.
Concordia operates out of facilities in Oakville, Ontario; Bridgetown,
Barbados; Kansas City, Missouri; Chicago, Illinois and Charlottesville,
SOURCE Concordia Healthcare Corp.
For further information:
please visit www.concordiarx.com or contact:
416-815-0700 x 225